User menu

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.

Bibliographic reference Ip, Emilia ; Farrell, Geoff ; Hall, Pauline ; Robertson, Graham ; Leclercq, Isabelle. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.. In: Hepatology, Vol. 39, no.5, p. 1286-96 (2004)
Permanent URL http://hdl.handle.net/2078.1/121984
  1. Ratziu, Gastroenterology, 118, 1117 (2000)
  2. Bacon Bruce R., Farahvash Mohammad J., Janney Christine G., Neuschwander-Tetri Brent A., Nonalcoholic steatohepatitis: An expanded clinical entity, 10.1016/0016-5085(94)90235-6
  3. Dixon, Gastroenterology, 21, 91 (2001)
  4. Bugianesi, Gastroenterology, 123, 134 (2002)
  5. Powell, HEPATOLOGY, 11, 74 (1990)
  6. Weltman, Gastroenterology, 111, 1645 (1996)
  7. Weltman, HEPATOLOGY, 27, 128 (1998)
  8. Ip, HEPATOLOGY, 38, 123 (2003)
  9. Lee S S, Pineau T, Drago J, Lee E J, Owens J W, Kroetz D L, Fernandez-Salguero P M, Westphal H, Gonzalez F J, Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators., 10.1128/mcb.15.6.3012
  10. Leung, Toxicol Lett, 85, 143 (1996)
  11. Jedlitschky, Advan Enzyme Regul, 33, 181 (1993)
  12. Guéraud, J Lipid Res, 40, 152 (1999)
  13. Delerive, J Biol Chem, 274, 32048 (1999)
  14. Poynter, J Biol Chem, 273, 32833 (1998)
  15. Macdonald, Gastroenterol Hepatol, 16, 599 (2001)
  16. Seki, J Hepatol, 37, 56 (2002)
  17. Leclercq, J Clin Invest, 105, 1067 (2000)
  18. Kumagai, Biochem Biophys Res Commun, 273, 437 (2000)
  19. Curzio, Int J Tissue React, 7, 137 (1985)
  20. Lee, J Clin Invest, 96, 2461 (1995)
  21. Parola, Biochem Biophys Res Commun, 222, 261 (1996)
  22. George, J Hepatol, 39, 756 (2003)
  23. Leclercq, J Hepatol, 37, 206 (2002)
  24. Theory and Practice of Histological Techniques. 2nd ed. New York: Churchill-Livingstone; 1980: 187-188.
  25. Willinger, Virchows Archives B Cell Pathology, 62, 237 (1992)
  26. Stärkel, J Hepatol, 39, 538 (2003)
  27. Iredale, HEPATOLOGY, 24, 176 (1996)
  28. Watanabe, J Hepatol, 33, 224 (2000)
  29. Chitturi, Semin Liver Dis, 21, 27 (2001)
  30. Day, HEPATOLOGY, 27, 1463 (1998)
  31. Mancini, FEBS Lett, 491, 154 (2001)
  32. Chou, J Biol Chem, 277, 24484 (2002)
  33. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR  Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells, 10.1161/01.cir.99.24.3125
  34. Rival, Eur J Pharmacol, 435, 143 (2002)
  35. Kono, Am J Physiol Gastrointest Liver Physiol, 280, g1289 (2001)
  36. Miyahara, J Biol Chem, 275, 35715 (2000)
  37. Hellemans, Gastroenterology, 124, 184 (2003)
  38. Kon, Biochem Biophys Res Commun, 291, 55 (2002)
  39. Iredale, J Clin Invest, 102, 538 (1998)
  40. Kovalszky, Scand J Gastroenterol, 33, 51 (1998)
  41. Abraham, J Biol Chem, 275, 15220 (2000)
  42. Murphy, J Biol Chem, 274, 5830 (1999)
  43. Inoue, FASEB J, 17, 268 (2002)
  44. Williams, J Hepatol, 32, 754 (2000)
  45. Paradis, HEPATOLOGY, 34, 738 (2001)
  46. Paradis, HEPATOLOGY, 30, 968 (1999)
  47. Poulos, Am J Physiol Gastrointest Liver Physiol, 273, g804 (1997)
  48. Palmer, Mol Pharmacol, 53, 14 (1998)
  49. Hertz, Toxicol Lett, 102, 85 (1998)
  50. Marx, Circ Res, 90, 703 (2002)